Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis.

Related Articles

Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis.

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):617-623

Authors: Janus N, Launay-Vacher V

Abstract
INTRODUCTION: The increased incidence of cancer in hemodialysis patients has been discussed since the mid-70s. Today, physicians regularly encounter situations where they must manage the prescription of anticancer drugs in hemodialysis patients. Areas covered: Hemodialysis patients are at risk of dose-related toxicities due to pharmacokinetic modifications. Hemodialysis patients are at risk of therapeutic drug removal during their hemodialysis session, which may result in a loss of efficacy. In the advent of novel immunotherapies, particularly tumor vaccines, there is an increased theoretical risk of pharmacodynamic modification. Indeed, pharmacodynamic modifications have already been reported for viral vaccines. Expert opinion: It is important to consider all of the potential pharmacokinetic/pharmacodynamic modifications before prescribing anticancer drugs in hemodialysis patients. However, pharmacokinetic/pharmacodynamic modification should not be considered a contraindication for anticancer drug use in hemodialysis patients, rather, clinicians should be aware of the need individualize treatment according to available recommendations.

PMID: 28537215 [PubMed - in process]

http://ift.tt/2qj14oM